PRKAA1 and metabolic disease: The data presented in this study that IQGAP1 binds AMPK and is required for maximum activation of AMPK raise the possibility that the interaction between AMPK and IQGAP1 could be a potential target for the development of new therapeutic agents for metabolic disorders.